MELT-300 Statistically Superior for Procedural Sedation Compared to All Comparator Treatment Arms, Including Midazolam 3mg (P=0.0129) and Ketamine 50mg (P=0.0096) MELT-300 Treatment Arm 50% Less Likely to Require Rescue Sedation Compared to Midazolam (P=0.0198) MELT-300 Treatment Arm 66% Less

Top-Line Results Expected by Year-End NASHVILLE, Tenn. --(BUSINESS WIRE)--Oct. 27, 2022-- Melt Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company developing novel approaches for procedural sedation and analgesia, today announced the dosing of the last patient in its Phase 2 pivotal

Bioavailability of MELT-210 Compares Favorably to Reference Drug NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation and analgesia, today announced top-line results of its phase 1 pharmacokinetics

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the addition of Brad Osborne as Chief Financial Officer. Osborne brings 20 years of extensive finance and accounting

Company Actively Dosing Patients for Phase 2 Pivotal Efficacy Study for MELT-300; Full Enrollment Followed by Readout on Topline Data Expected by End of Second Quarter of 2022 NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing